The era of pharmacovigilance and the need of pharmacovigilance in psychiatry: A review
Abstract
According to WHO, Adverse drug reaction (ADR) is defined as “any response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function”. Adverse drug reactions occur almost daily in every health care institution and can adversely affect a patient’s quality of life (QOL), often causing considerable morbidity and mortality. With the setting up of the Pharmacovigilance Program in India, it is important for all psychiatrists, pharmacist and nurses to familiarize themselves with the key principles of this science, and to apply the principle of Pharmacovigilance for the welfare of our patients and the entire health care community.
Keywords: Adverse drug reaction (ADR), prophylaxis, diagnosis, patient’s quality of life (QOL)
Downloads
References
2. Stephanie N. Schatz, Phar m.D., BCPS; and Robert J. Weber, Phar m.D., BCPS.Adverse Drug Reactions.CNS/Pharmacy Practice. PSAP 2015; 21-25
3. Charu Bahri.How India tackles adverse drug reactions – by ignoring data.Feb 08, 2016 • 09:30 pm. IndiaSpend.com
4. Spina, Edoardo & Trifirò, Gianluca & Patrizio Caputi, Achille. (2016). Pharmacovigilance in Psychiatry: An Introduction. 3-7. 10.1007/978-3-319-24741-0_1.
5. Rajkumar RP, Melvin G. Pharmacovigilance for psychiatrists: An introduction.Indian J Psychiatry 2014; 56:176-81
6. Lock, Stephen, John M. Last, and George Dunea, eds.The Oxford Illustrated Companion to Medicine.Oxford: Oxford University Press, 2001.
7. Prashant N Amale*, Deshpande SA, Nakhate YD and Arsod NA.Pharmacovigilance Process in India: An overview. J Pharmacovigil 2018; 6(2):259
8. Rittmannsberger H, Meise U, Schauinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment: Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 14:33-40.
9. March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162:836-46.
10. Nassir Ghaemi S, Shirzadi AA, Filkowski M. Publication bias and the pharmaceutical industry: The case of lamotrigine in bipolar disorder. Medscape J Med 2008; 10:211.
11. World Health Organization (1984) World Health Organization Collaborating Centre for International Drug Monitoring, Geneva.
12. World Health Organization (2002) World Health Organization Collaborating Centre for International Drug Monitoring. The Importance of Pharmacovigilance Safety Monitoring of Medicinal Products, Geneva.
13. Kim JH, Scialli AR, Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011; 122:1-6.
14. Ravi Philip Rajkumar and George Melvin.Pharmacovigilance for psychiatrists: An introduction Indian J Psychiatry. 2014; 56(2):176–181.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.